Villar Lm, García-Barragán N, Espiño M, Roldán E, Sádaba Mc, Gómez-Rial J, González-Porqué P, Alvarez-Cermeño Jc
Department of Neurology and Immunology, Hospital Ramón y Cajal, Madrid, Spain.
Mult Scler. 2008 Mar;14(2):183-7. doi: 10.1177/1352458507082046. Epub 2007 Oct 17.
Oligoclonal IgM bands (OCMB) against myelin lipids predict an aggressive multiple sclerosis (MS) course. However, the clinical significance of OCMB without lipid specificity, present in other MS patients, remains unknown. We describe here a characterization of these antibodies and study their role in MS progression. Fifty-four MS patients showing CSF-restricted OCMB were included in this study at disease onset and followed-up during 61.1 +/- 2.7 months. The specificity of OCMB and the CSF B-cell profile were investigated. A second CSF IgM study was performed in a group of eight patients. Thirty-eight patients showed OCMB against myelin lipids (M+L+) and other sixteen had OCMB lacking this specificity (M+L-). The CD5+ B cell subpopulation, responsible for most persistent IgM responses, was considerably higher in M+L+ than in M+L- patients (3.3 +/- 0.6% versus 0.8 +/- 0.2, P = 0.009). In addition, M+L+ bands persisted during disease course, while M+L- disappeared during follow-up. M+L+ patients suffered more relapses (4.2 +/- 0.6 versus 1.6 +/- 0.3, P = 0.002) and reached higher disability (EDSS score of 2.2 +/- 0.2 versus 1.2 +/- 0.2, P = 0.02) than M+L- group. These data corroborate that anti-lipid OCMB associate with an aggressive MS course and show that OCMB that do not recognize myelin lipids represent a transient immune response related to a more benign disease course.
针对髓磷脂脂质的寡克隆IgM条带(OCMB)预示着多发性硬化症(MS)病情进展迅速。然而,其他MS患者体内存在的无脂质特异性的OCMB的临床意义仍不明确。我们在此描述了这些抗体的特征,并研究了它们在MS病情进展中的作用。本研究纳入了54例在疾病发作时出现脑脊液局限性OCMB的MS患者,并在61.1±2.7个月期间进行随访。研究了OCMB的特异性和脑脊液B细胞谱。对一组8例患者进行了第二次脑脊液IgM研究。38例患者出现针对髓磷脂脂质的OCMB(M+L+),另外16例患者的OCMB缺乏这种特异性(M+L-)。负责大多数持续性IgM反应的CD5+B细胞亚群在M+L+患者中比M+L-患者明显更高(3.3±0.6%对0.8±0.2,P=0.009)。此外,M+L+条带在病程中持续存在,而M+L-条带在随访期间消失。与M+L-组相比,M+L+患者复发更多(4.2±0.6对1.6±0.3,P=0.002),残疾程度更高(扩展残疾状态量表评分为2.2±0.2对1.2±0.2,P=0.02)。这些数据证实,抗脂质OCMB与MS病情进展迅速相关,并表明不识别髓磷脂脂质的OCMB代表与更良性病程相关的短暂免疫反应。